BiotechTube

ABP-450 + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Migraine

Conditions

Migraine

Trial Timeline

Mar 1, 2021 → Aug 6, 2024

NCT ID
NCT04845178

About ABP-450 + Placebo

ABP-450 + Placebo is a phase 2 stage product being developed by AEON Biopharma for Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT04845178. Target conditions include Migraine.

What happened to similar drugs?

20 of 20 similar drugs in Migraine were approved

Approved (20) Terminated (1) Active (0)
✅Galcanezumab + ErenumabEli LillyApproved
✅Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
✅Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
✅tramadol HCl/acetaminophenJohnson & JohnsonApproved
✅topiramate; almotriptan malateJohnson & JohnsonApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mgAbbVieApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04849988Phase 2Completed
NCT04845178Phase 2Completed

Competing Products

20 competing products in Migraine

See all competitors
ProductCompanyStageHype Score
DFN-11Dr. Reddy's LaboratoriesPhase 2
32
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed)Dr. Reddy's LaboratoriesPhase 1
26
DFN-11Dr. Reddy's LaboratoriesPhase 3
37
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B)Dr. Reddy's LaboratoriesPhase 2
32
DFN-15Dr. Reddy's LaboratoriesPhase 2
32
ABP-450AEON BiopharmaPhase 2
17
Lasmiditan + PlaceboEli LillyPhase 3
40
Placebo + LY2300559Eli LillyPhase 2
27
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
29
Lasmiditan + PlaceboEli LillyPhase 2
35
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Galcanezumab + ErenumabEli LillyApproved
43
Aricept (donepezil hydrochloride)EisaiPhase 2
35
E2007EisaiPhase 2
35
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
43
Galcanezumab + PlaceboEli LillyPhase 3
40
Lasmiditan + PlaceboEli LillyPhase 2
35
Galcanezumab + PlaceboEli LillyPhase 3
40